Published in Frontiers in Oncology – 2025
Collaborator: Johnson & Johnson
Authors: Beth Faiman, Hoa H. Le, Julie Laurent, Saurabh Patel, Agne Paner-Straseviciute, Xinke
Zhang, Joseph Mikhae
Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed/refractory multiple myeloma (RRMM) represents a significant challenge as the disease relapses or becomes
refractory to previous treatments. Recent advances in therapy have expanded RRMM treatment options. This study aimed to gain a deeper understanding of patients’ treatment preferences regarding available therapeutic options.
